MD, MBA (Finance, NYU-Stern), certificate in financial modeling (Wharton).
*Tipranks profile not accurate as doesn't pick up my premium ratings.
Insights contributor: SumZero's Institutional Platform (www.sumzero.com).
Founder: Vasuda Healthcare Analytics (premium U.S. Biotech/pharma research, 2nd ranked biotech/pharma premium service on SA Marketplace). Subscribers include hedge fund managers, hedge fund analysts, sell-side analysts, financial advisors, etc.
I was one of the top 10 analysts among over 100 for Smartkarma Intelligent Investing (smartkarma.com) covering Asian Healthcare.
Registered investment advisor in Massachusetts for own asset management firm, Vasuda Capital Management.
Founder and Sponsor: Vasuda Global Orphan/Rare Diseases Index, first global equity index representing the orphan/rare disease sector (vasudaindices.com)
Linkedin profile: https://www.linkedin.com/in/bhavneeshsharmamd/
Having always been a learning machine, I speak five languages, have worked as a sales agent, project manager, translator, computer consultant, software engineer, built a house with my own hands, published books and essays on literature, philosophy and art, have written for magazines of various kinds in different countries.
After retiring early in 2004, little by little, I have become a fund manager for some friends and myself, following the principles of value investing laid out by Benjamin Graham, Phil Fisher, Charlie Munger and Warren Buffett. You can read about my thoughts on a suitable portfolio structure for early retirees here.
My articles should not be considered to be any kind of investment advice. What suits me well is not necessarily good for others, as successful investing is somewhat like a marriage: If only one is perfect, the marriage won’t work. So please do your own research and remember Benjamin Graham's advice: “The investor’s chief problem — and even his worst enemy — is likely to be himself.”
I run a very concentrated portfolio with 10-15 positions and invest for the long term. As of 12/2016, my largest position is Theravance Biopharma (TBPH), a company I had intensively and extensively researched long before any sell-side analyst noticed the stock. You can find my early work on TBPH on this site and my comprehensive in-depth research reports on all important pipeline assets here. I correctly predicted the evolution of the new GOLD guidelines for COPD, the sales trajectory of Vibativ and GSK's new Ellipta product range. My reports have been far ahead (in terms of depth, scope and reliability) of all sell-side work on TBPH. That said, I obviously make mistakes as well, although I've yet to make one that costs me serious money.
Other long-time favorites of mine are DaVita (DVA), IBM and a few European small caps which I have also partly covered on Seeking Alpha, e.g. Admiral (AMIGF), Fuchs Petrolub (FUPEF).
Manoj Madhavan, CFA, CFP, is a Principal at Oxford Chase Advisors LLC, a Dunwoody, Georgia based Registered Investment Advisory (RIA) firm. His investment philosophy is loosely based on Warren Buffet’s principles of value investing.
Manoj was born in Tiruchirapalli (Trichy), India. He has a Bachelor's degree in Engineering from Indian Institute of Technology, Varanasi, India, a Master's degree in Engineering from Louisiana State University, Baton Rouge and an Executive MBA from Emory University, Atlanta.
Over 35 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action; and biotech. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
Lawrence Meyers is the CEO of PDL Capital, which brokers financing, strategic investments, and distressed asset purchases between private equity firms and businesses of all stripes.
He was the first U.S. journalist to cover the payday loan sector for The Motley Fool. He is a frequent contributor on matters of personal finance and stock market investing to SeekingAlpha.com, InvestorPlace.com, WyattResearch.com, Bloggernews.net, LearnBonds.com, and blogs at http://www.ichabodcranium.com.
His work has been praised for its insight, humor, and specifics of working financial psychology into his analysis of personal finance matters and stock market investing. He attributes his skill to his many years writing for dramatic television. He has written over 24 hours of television and produced over 60 hours.
He consults for institutional investors on all aspects of the domestic and foreign alternative financial services industry, including legislative and regulatory issues. In 2010, Meyers began consulting for crisis communications firms, providing articles and videos to support their various clients. He is also developing business plans for the alternative financing, production, and distribution of creative content.
As a crisis communications consultant, he has drawn upon his expertise in various other fields including: economics, chemistry, public policy, fragrances, hair products, regulatory corruption, political communications, student loans, public and for-profit education, filmed entertainment, junk science, and pop culture criticism.
He is also the author of Teacher of the Year: The Mystery and Legacy of Edwin Barlow, which 60 Minutes correspondent Steve Kroft has praised; Inside the TV Writer's Room: Practical Advice for Succeeding in Screenwriting; and Bond Forever: A Film Buff's Cinematic Analysis of the James Bond series.
Lawrence has more than 20 years of personal finance and investing experience, and has covered stocks across virtually every sector of the market. He is one of the nation’s experts on consumer credit, and frequently consults for hedge funds and private equity via his Council Member status at Gerson Lehman Group, and as a member of Coleman Research Group’s Executive Forum.
His Op-Eds and Letters to the Editor have appeared in over two dozen major newspapers.
As with any articles regarding investments, you should never rely on information you read without doing your own due diligence. My articles contain my honest, forthright and carefully considered personal opinion, and conclusions, containing information derived from my own research. This may include discussions with management. I do not repeat "talking points" but may quote management from an interview. I am never influenced by third parties in arriving at my conclusions. Do not solely rely on my articles or anyone else's when making an investment decision. Always contact your financial advisor before investing in any security.
You can contact Lawrence at PDLCapital66@gmail.com.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I am a private investor based out of Toronto, Canada and I have been investing since 2003. After 8 years in Corporate Finance with a Canadian Telecom company I have decided to dedicate myself full-time to the capital markets. I write on Seeking Alpha to demonstrate my financial analysis and writing skills across a variety of industries and to take advantage of any story-based trading opportunity that may arise. My passion and greatest depth of knowledge is on Canadian small cap stocks and I consider my blog posts to be some of my best work. I am interested in any freelance opportunities that may arise outside of Seeking Alpha on Canadian or American listed stocks.
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
I am an activist investor in US and Chinese stocks. I was previously an investment banker in New York Hong Kong and London for 9 years, focused on Equity Capital Markets. I look at both long ideas and short ideas and typically focus on a small number on names where I can spend the time to conduct very deep research. I spend my time living between Los Angeles and Beijing, China.
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
With over 8 years in the medical field, and 4 years serving the U.S. Army's Medical Corp, I have a large interest, and unique insight into the financial future of the healthcare field.
It is my intent to consider and dissect the newest 'up and coming' technology from a health care providers point of view.
I will provide all of the facts necessary to make actionable decisions, with the utmost integrity.
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a Technology Transfer Officer at UCLA. He has a B.S. from Penn State University and an MBA from Rutgers University.
His WEB site at www.raygent.com is currently focused in biopharmaceuticals, genomics and clinical diagnostics . Mr. Raynovich has extensive expertise in marketing and product development and provides business development consulting to early stage companies in biotechnology, diagnostics and imaging.
The Rayno Life Science Portfolio was published on www.raygent.com and other trade media.
Articles have been published on the following topics: Alzheimer Disease,Biomarkers, Genomics,Molecular Diagnostics, Oncology Drugs, Personalized Medicine, Targeted Therapy, Technology Trends, H1N1 and Government Policy on biotechnology.
The Life Science Portfolio is up over 80% over a 24 mo. period as of 5/30/14and among the life science portfolio winners are ABAX, ALXN, AMRI, BIIB, CBST, GPRO, ILMN, QDEL,REGN, SGEN, and VPHM.
I am a retired college faculty in Philosophy, with specializations in Ethics, Socio-political Theory and Rational Choice/Decision Theory. My teaching focus was on Business Ethics, Medical Ethics and Logic. After retirement I freelanced as a Grant Writer/Fund Raising Consultant. I have taught at Washington University in St. Louis, the University of Missouri - St. Louis, and St. Louis Community College.
I believe that potential investments ought to be evaluated through an examination of their fundamentals - i.e., fundamental analysis. Those investments can then be analyzed with respect to whatever criteria an investor may wish to bring to bear, but at least the investments they make will be more or less fundamentally sound. For me, one of the more important features of an investment (after fundamentals are satisfied) is dividend yield. I expect my investment to earn money for me.
I also believe that the day of the "traditional" investment strategy based on one's age/proximity to retirement is over. To be sure, one wants to put one's money in places where it is more secure, but in the day and age of internet-based investment services, a variety of ETFs, and reasonably safe investment vehicles, there is no need for retired people to stick the bulk of their assets in relatively unprofitable treasury notes and bonds.
Mr. Rosenman has nearly 15-years executive experience in the health and wellness sectors, including weight loss, cosmetics skincare and nutrition, both Rx and OTC. Expertise areas include strategic market and product planning and corporate development (evaluation, recommendation and execution of strategic alliances and acquisitions). A MBA graduate of the Sweigart School of Business at Rider University, Rosenman devotes a portion of time back to the collegiate community as a graduate-level adjunct professor for healthcare marketing, consumer behavior and strategic planning. He has several published works in the field of U.S health and wellness, including a focus on how nutritional ingredients will transition into Rx space, specifically with lipid and herbal managment. His current professional role is with one of the fastest growing nutritional companies in the U.S., which also produces Rx and OTC products. He has served as an advisory board member to various organizations in the healthcare field, from venture start-ups to top global enterprises. Mr. Rosenman is a Senior Advisor with Guidepoint Global and is called upon by large institutional investors for insight and expert opinion on healthcare market opportunities (to date he has advised on more than $2 billion USD of related transactions/funding).
I am currently employed by a Fortune 20 company, on any given day I am assessing risk management and the financial health of various companies. My time is spent looking at charts and numbers all day and I specialize in statistical analysis. I use the writers of various finance sites for my investing ideas, then do my own research prior to investing.
Thanks to those of you that have given me feedback and responded to my messages. I have found the writers at Seeking Alpha to be very accommodating and informative.
Team StockMatusow.com research and writers are:
Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com.
Scott is an independent investor/writer/trader and team leader of StockMatusow.com.
He has have about 17 years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account.
Scott has had the most success in trading/investing in smaller cap growth companies. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis.
Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. Additionally, Dan is a Scientist and inventor. He has 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small caps. Dan utilizes his experience reading and reviewing scientific literature to evaluate prospects for success. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunoncology focused approaches. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team.
Places you can follow Scott are:
Places to follow Dan are: